Aprinoia Therapeutics is dedicated to establish a drug discovery and early development company that is based on innovation and scientific rigor and integrity.
Our goal is to create novel products to meet critical patient needs, including:
1) Novel imaging-based diagnostic tools to improve the detection of occurrence, progression, and regression of neurological diseases; and
2) Novel therapies to improve the treatment of human neurological conditions.
Our goal is to create novel products to meet critical patient needs, including:
1) Novel imaging-based diagnostic tools to improve the detection of occurrence, progression, and regression of neurological diseases; and
2) Novel therapies to improve the treatment of human neurological conditions.
Location: Taiwan, Taipei
Employees: 11-50
Total raised: $11M
Founded date: 2015
Investors 3
Funding Rounds 1
| Date | Series | Amount | Investors |
| 16.01.2018 | Series B | $11M | KTB Networ... |
Mentions in press and media 3
| Date | Title | Description |
| 24.08.2023 | Wilbur Ross' SPAC backtracks on merger with Alzheimer's-focused biotech | Don’t count on the triumphant return of biotech special purpose acquisition company deals quite yet. Despite Wilbur Ross’ own blank check company making one of the first announcements for the sector this year, it turns out that deal has now... |
| 17.01.2018 | Taiwan’s Aprinoia Therapeutics raises $11m co-led by KTB Network, DCI Partners | Premium Taiwan-based Aprinoia Therapeutics Inc, a clinical-stage neuroscience biotech company, said it has completed its $11 million Series B funding round co-led by Korea’s KTB Network and Japan’s DCI Partners. Continue reading this story ... |
| 16.01.2018 | Aprinoia Therapeutics Closes US$11M Series B Financing | Aprinoia Therapeutics Inc., a Taipei, Taiwan-based clinical-stage neuroscience biotech company, focuses on tau, alpha-synuclein, and novel targets for neurodegenerative diseases, completed its US$11.1m Series B funding round. The round was ... |